Provided by Tiger Fintech (Singapore) Pte. Ltd.

Evoke Pharma

2.50
+0.17107.34%
Post-market: 2.500.00000.00%18:22 EDT
Volume:12.33K
Turnover:29.59K
Market Cap:3.73M
PE:-0.89
High:2.53
Open:2.30
Low:2.30
Close:2.33
Loading ...

Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting Gimoti®

THOMSON REUTERS
·
03 Dec 2024

Evoke Pharma Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.
·
10 Nov 2024

Evoke Pharma Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
09 Nov 2024

Evoke Pharma Q3 2024 GAAP EPS $(0.94) Misses $(0.38) Estimate, Sales $2.70M Miss $3.36M Estimate

Benzinga
·
08 Nov 2024

Evoke Pharma Inc Qtrly Net Loss Was Approximately $1.3 Million, or $0.94 per Share

THOMSON REUTERS
·
08 Nov 2024

Evoke Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
06 Nov 2024

Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit

Simply Wall St.
·
04 Nov 2024

S&P 500 Moves Higher; Philips Shares Plunge After Q3 Earnings

Benzinga
·
29 Oct 2024

Evoke Pharma Shares Rise 70% on Gimoti Data in GLP-1 Users

Dow Jones
·
28 Oct 2024

Evoke stock rockets 90% on study of Gimoti in GLP-1 users

seekingalpha
·
28 Oct 2024

Evoke Pharma trading halted, volatility trading pause

TIPRANKS
·
28 Oct 2024

Evoke Pharma Shares More Than Double After Study Shows Potential of Co's Nasal Spray as Supportive Care for Glp-1 Therapy

THOMSON REUTERS
·
28 Oct 2024

Evoke Pharma Says Study Showed Gimoti Reduces Emergency Visits in Diabetic Gastroparesis Patients Using GLP-1; Shares Surge Pre-Bell

MT Newswires Live
·
28 Oct 2024

BRIEF-Evoke Pharma & Eversana Announce Statistically Significant Improvement In Patient Outcomes For Glp-1 Users With Diabetic Gastroparesis Using Gimoti®

Reuters
·
28 Oct 2024

BUZZ-Evoke surges on positive study for nasal spray

Reuters
·
28 Oct 2024

Top Premarket Gainers

MT Newswires Live
·
28 Oct 2024

Evoke Pharma Shares More Than Triple Premarket After Study Shows Potential of Co's Nasal Spray as Supportive Care for Glp-1 Therapy

THOMSON REUTERS
·
28 Oct 2024

Evoke, EVERSANA announce statistically significant improvement using GIMOTI

TIPRANKS
·
28 Oct 2024

Evoke Pharma & Eversana Announce Statistically Significant Improvement in Patient Outcomes for Glp-1 Users With Diabetic Gastroparesis Using Gimoti®

THOMSON REUTERS
·
28 Oct 2024